GlassScriptPhysician profile
Brian Delmonaco
NPI 1245338185
$1,739.84
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.00 · 2021: $29.88 · 2022: $791 · 2023: $791 · 2024: $116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $650 · Food and Beverage: $257.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $650.00 |
| Food and Beverage | $257.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exthera Medical Corporation | $1,403.45 | 2021-2023 | |
| Abiomed | $77.53 | 2024 | Impella |
| United Therapeutics Corporation | $67.34 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $54.99 | 2023 | Tezspire, Tagrisso |
| Mylan Specialty L.P. | $38.08 | 2023 | Yupelri |
| Glaxosmithkline, LLC. | $32.19 | 2023-2024 | Nucala |
| Regeneron Healthcare Solutions, INC. | $29.25 | 2023 | Dupixent |
| Merck Sharp & Dohme LLC | $25.01 | 2024 | Winrevair |
| Zoll Circulation INC | $12.00 | 2020 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Delmonaco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.